WSTNEUTRAL

WST Return on Equity (ROE) Analysis

19.1%

Updated 1515h ago·SEC filings & market data

Key Takeaway

Return on equity (ROE) measures how much profit a company generates for each dollar of shareholder equity; 19.1% means West Pharmaceutical produces $0.191 in profit per $1 of equity.

Sector Performance

65th percentile

WST

19.1%

Sector Median

13.2%

Sector Avg

16.4%

Prior Period

15.5%(Apr 2026)

↑ Improving
📊

Deep Analysis

Return on equity (ROE) measures how much profit a company generates for each dollar of shareholder equity; 19.1% means West Pharmaceutical produces $0.191 in profit per $1 of equity.

At 19.1%, the ROE sits above the sector median of 13.3%, placing the company in the 66th percentile among its sector peers. The trend is not available: the year-over-year change is N/A and the quarter-over-quarter change is N/A, so no recent direction can be determined. The combination of a solidly above-median ROE and a missing trend leaves a level-based positive but no evidence of improving or deteriorating momentum. This creates a neutral opportunity: the high efficiency is a plus, but the lack of trend data prevents a stronger

Frequently Asked Questions

What does the Return on Equity (ROE) tell investors about WST?

ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.

How is the Return on Equity (ROE) calculated?

Return on Equity (ROE) is calculated as: Net Income / Shareholders' Equity.

The Formula

Net Income / Shareholders' Equity

Why It Matters

ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.

Advertisement

Master WST's Valuation

Get the complete institutional research report covering all fundamental and technical metrics.

View full WST research report →

Free account — no credit card

WST

19.1%

Sector Median

13.2%

Sector Avg

16.4%

How WST's Return on Equity (ROE) compares to sector peers.

Not financial advice. Research tool only. Data may be delayed.